Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

@inproceedings{Harder2012MulticentrePI,
  title={Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer},
  author={Jan Harder and G Ihorst and Volker Heinemann and Ralf-Dieter Hofheinz and Markus Hermann Moehler and Peter Buechler and Guenter Kloeppel and Christoph R{\"o}cken and Michael Bitzer and Stefan Hubert Boeck and Esther Endlicher and Anke C Reinacher-Schick and C. Schmoor and Michael Geissler},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody trastuzumab combined with capecitabine in the patients with pancreatic cancer and HER2 overexpression.Methods:Primary endpoint was progression-free survival (PFS) after 12 weeks. A total of 212… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
33 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…